<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05045235</url>
  </required_header>
  <id_info>
    <org_study_id>PI2021_843_0158</org_study_id>
    <nct_id>NCT05045235</nct_id>
  </id_info>
  <brief_title>Optimization of Drug Prescriptions in the Care Pathway for the Elderly, With the Final Objective of Reducing the Iatrogenic Risk</brief_title>
  <acronym>IATROPREV</acronym>
  <official_title>Optimization of Drug Prescriptions in the Care Pathway for the Elderly, With the Final Objective of Reducing the Iatrogenic Risk.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The IATROPREV project is an organizational innovation experimentation project, carried out in&#xD;
      Hauts-de-France by the University hospitals of Amiens and Lille, the ARS and the URPS Doctors&#xD;
      and Pharmacists of Hauts-de-France and following to the social security financing law of&#xD;
      2018, allowing experimentation with new organizations in the health sector, according to&#xD;
      article 51. The objectives of this course are to improve the relevance of prescription in&#xD;
      elderly people with multiple drugs as well as, the coordination of care between the city and&#xD;
      the hospital through the sharing of information and the establishment of multi-professional&#xD;
      consultations between the various care actors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of side effect number in ederly with polymedicated drugs</measure>
    <time_frame>up to 4 years</time_frame>
    <description>Change of side effect number in ederly with polymedicated drugs</description>
  </primary_outcome>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Iatrogenic Effect</condition>
  <condition>Prescription</condition>
  <condition>Follow-up</condition>
  <condition>Consultation</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patient hospitalized in the geriatric medicine department with olymedicated drugs&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient hospitalized in the geriatric medicine department&#xD;
&#xD;
          -  Potential involvement of a drug in hospitalization or potential or proven iatrogenic&#xD;
             event during hospitalization;&#xD;
&#xD;
          -  Numerous therapeutic modifications (3 or more);&#xD;
&#xD;
          -  Drug interaction or introction of a new drug with one or more drug interactions;&#xD;
&#xD;
          -  Medicinal product with a narrow therapeutic marge drug requiring close monitoring.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient non hospitalized in the geriatric medicine department&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Frédéric BLOCH, MD</last_name>
    <phone>03 22 45 57 20</phone>
    <email>bloch.frederic@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Amiens University Hospital</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric BLOCH, MD</last_name>
      <phone>03 22 45 57 20</phone>
      <email>bloch.frederic@chu-amiens.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 7, 2021</study_first_submitted>
  <study_first_submitted_qc>September 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>iatrogenic</keyword>
  <keyword>prescription</keyword>
  <keyword>follow-up</keyword>
  <keyword>consultation</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

